Literature DB >> 23614865

[Cohort multiple randomized controlled trial: a solution for the evaluation of multiple interventions].

H M Lenny Verkooijen1, Kit Roes, Carla H van Gils.   

Abstract

The standard randomized controlled trial (RCT) does not appear to be the most suitable design for the fast and efficient simultaneous evaluation of multiple interventions for the same condition. The cohort multiple randomized controlled trial (cmRCT) design offers the opportunity to perform randomized trials for multiple interventions simultaneously and is a promising alternative for the classic RCT. The basis of the cmRCT is an observational cohort of patients with the same condition. The patients will generally undergo standard treatment. The patient characteristics are captured at baseline and outcome measures are captured at fixed points of time. Eligible patients within the observational cohort are identified for each new intervention, some of whom will be randomly selected and offered the new intervention. The other eligible patients will not be approached and will undergo the standard treatment. The same process can be simultaneously repeated for other interventions. Advantages include the ability to facilitate multiple simultaneous randomized evaluations, the improved comparability between trials and the patient-centered informed consent procedure.

Entities:  

Mesh:

Year:  2013        PMID: 23614865

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  9 in total

Review 1.  Can we deliver randomized trials of focal therapy in prostate cancer?

Authors:  Hashim U Ahmed; Viktor Berge; David Bottomley; William Cross; Rakesh Heer; Richard Kaplan; Tom Leslie; Chris Parker; Clare Relton; Richard Stephens; Matthew R Sydes; Lindsay Turnbull; Jan van der Meulen; Andrew Vickers; Timothy Wilt; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-04-22       Impact factor: 66.675

Review 2.  Perinatal epidemiology: Issues, challenges, and potential solutions.

Authors:  Konstantinos Giannakou
Journal:  Obstet Med       Date:  2020-09-01

3.  Pain exposure physical therapy (PEPT) compared to conventional treatment in complex regional pain syndrome type 1: a randomised controlled trial.

Authors:  Karlijn J Barnhoorn; Henk van de Meent; Robert T M van Dongen; Frank P Klomp; Hans Groenewoud; Han Samwel; Maria W G Nijhuis-van der Sanden; Jan Paul M Frölke; J Bart Staal
Journal:  BMJ Open       Date:  2015-12-01       Impact factor: 2.692

4.  Active patient participation in the development of an online intervention.

Authors:  Inge Renske van Bruinessen; Evelyn M van Weel-Baumgarten; Harm Wouter Snippe; Hans Gouw; Josée M Zijlstra; Sandra van Dulmen
Journal:  JMIR Res Protoc       Date:  2014-11-06

5.  Commentary: considerations for using the 'Trials within Cohorts' design in a clinical trial of an investigational medicinal product.

Authors:  Anna C Bibby; David J Torgerson; Samantha Leach; Helen Lewis-White; Nick A Maskell
Journal:  Trials       Date:  2018-01-08       Impact factor: 2.279

Review 6.  Perforator-based flaps for the treatment of burn scar contractures: a review.

Authors:  C M Stekelenburg; R E Marck; P D H M Verhaegen; K W Marck; P P M van Zuijlen
Journal:  Burns Trauma       Date:  2017-02-27

7.  A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.

Authors:  Anna C Bibby; Natalie Zahan-Evans; Emma Keenan; Charles Comins; John E Harvey; Helen Day; Najib M Rahman; Janet E Fallon; Rachael Gooberman-Hill; Nick A Maskell
Journal:  Pilot Feasibility Stud       Date:  2022-09-03

8.  Alternative Randomized Trial Designs in Surgery: A Systematic Review.

Authors:  Simone Augustinus; Iris W J M van Goor; Johannes Berkhof; Lois A Daamen; Bas Groot Koerkamp; Tara M Mackay; I Q Molenaar; Hjalmar C van Santvoort; Helena M Verkooijen; Peter M van de Ven; Marc G Besselink
Journal:  Ann Surg       Date:  2022-07-22       Impact factor: 13.787

9.  PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study.

Authors:  E J Bass; N Klimowska-Nassar; T Sasikaran; E Day; F Fiorentino; M R Sydes; M Winkler; N Arumainayagam; B Khoubehi; A Pope; H Sokhi; T Dudderidge; H U Ahmed
Journal:  Contemp Clin Trials       Date:  2021-06-15       Impact factor: 2.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.